DY
NBIX icon

Dowling & Yahnke’s Neurocrine Biosciences NBIX Stock Holding History

Dowling & Yahnke’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-30,000
Closed -$483K – 273
2014
Q1 		$483K Sell
30,000
-22,957
-43% -$393K 0.06% 195
2013
Q4 		$495K Hold
52,957
– – 0.07% 188
2013
Q3 		$599K Hold
52,957
– – 0.09% 166
2013
Q2 		$709K Buy
+52,957
New +$651K 0.12% 156

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Dowling & Yahnke's NBIX Position: Q2 2014 in Review

Dowling & Yahnke sold out of Neurocrine Biosciences (NBIX) in Q2 2014, closing a stake of 30,000 shares — an estimated $483K sold.

Dowling & Yahnke first reported a position in NBIX in Q2 2013 and held it in 4 quarters. The position peaked at $709K in Q2 2013. 125 funds tracked by Wall St. Rank hold NBIX as of Q2 2014.

  • Dowling & Yahnke reported no remaining Neurocrine Biosciences position as of Q2 2014 after selling out during the quarter.
  • Dowling & Yahnke sold 30,000 Neurocrine Biosciences shares in Q2 2014, an estimated $483K.
  • Dowling & Yahnke first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 4 quarters.
  • Dowling & Yahnke's Neurocrine Biosciences position peaked at $709K in Q2 2013.
  • 125 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2014.

Based on Dowling & Yahnke's 13F filing for Q2 2014, filed 15 Aug 2014.